Chris Shibutani
Stock Analyst at Goldman Sachs
(3.40)
# 956
Out of 4,712 analysts
100
Total ratings
52%
Success rate
3.31%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Initiates: Buy | $135 | $85.91 | +57.14% | 1 | Dec 20, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $114.13 | +20.04% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $13.07 | +152.49% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $360.87 | -16.31% | 4 | Nov 1, 2024 | |
| ALKS Alkermes | Maintains: Buy | $32 → $30 | $29.65 | +1.18% | 6 | Oct 25, 2024 | |
| ERAS Erasca | Maintains: Buy | $3 → $3.5 | $2.57 | +36.19% | 6 | Oct 25, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $25.23 | +102.14% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $145.85 | +6.27% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $4.00 | - | 8 | Jul 12, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $3.08 | +159.74% | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $14.73 | +35.78% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $795.67 | -9.13% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $19.73 | +31.78% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $136.53 | +12.06% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $179.80 | -3.78% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.91 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $1.25 | $0.96 | +30.21% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $57.76 | +19.46% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $17.78 | -26.88% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $44.39 | -48.19% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.27 | +2,102.64% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $40.82 | +27.39% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.71 | +124.68% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $17.56 | +2.51% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $3.04 | +459.21% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.35 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.64 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.02 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.61 | - | 3 | May 2, 2017 |
Vaxcyte
Dec 20, 2024
Initiates: Buy
Price Target: $135
Current: $85.91
Upside: +57.14%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $114.13
Upside: +20.04%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $13.07
Upside: +152.49%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $360.87
Upside: -16.31%
Alkermes
Oct 25, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $29.65
Upside: +1.18%
Erasca
Oct 25, 2024
Maintains: Buy
Price Target: $3 → $3.5
Current: $2.57
Upside: +36.19%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $25.23
Upside: +102.14%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $145.85
Upside: +6.27%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $4.00
Upside: -
Revance Therapeutics
May 13, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $3.08
Upside: +159.74%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $14.73
Upside: +35.78%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $795.67
Upside: -9.13%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $19.73
Upside: +31.78%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $136.53
Upside: +12.06%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $179.80
Upside: -3.78%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.96
Upside: +30.21%
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $57.76
Upside: +19.46%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $17.78
Upside: -26.88%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $44.39
Upside: -48.19%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.27
Upside: +2,102.64%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $40.82
Upside: +27.39%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.71
Upside: +124.68%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $17.56
Upside: +2.51%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $3.04
Upside: +459.21%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.35
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.64
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.02
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $15.61
Upside: -